Research location
Tustin
California, United States
Research activity in Tustin
California, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 368 trials and 374 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Tustin
368 linked trials · page 1 of 8Empowering Patients' Lung Cancer Screening Uptake (Empower LCS/Call+)NCT07711691 · 2026-09-16 · 1 site observation
RECRUITING
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesNCT07743463 · 2026-08-31 · 1 site observation
RECRUITING
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 DiabetesNCT07743450 · 2026-08-28 · 1 site observation
RECRUITING
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood SugarNCT07754461 · 2026-08-24 · 1 site observation
RECRUITING
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related ComorbiditiesNCT07752979 · 2026-08-04 · 1 site observation
RECRUITING
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)NCT07654374 · 2026-07-17 · 1 site observation
RECRUITING
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or ObesityNCT07595549 · 2026-06-10 · 1 site observation
RECRUITING
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)NCT07607964 · 2026-05-28 · 1 site observation
RECRUITING
A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)NCT07409103 · 2026-02-18 · 1 site observation
RECRUITING
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinNCT07392190 · 2026-02-10 · 1 site observation
RECRUITING
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 DiabetesNCT07321886 · 2026-02-06 · 1 site observation
RECRUITING
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or OverweightNCT07202884 · 2025-09-30 · 1 site observation
RECRUITING
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseNCT07181109 · 2025-09-22 · 1 site observation
RECRUITING
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.NCT06991114 · 2025-07-09 · 1 site observation
RECRUITING
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseNCT07082738 · 2025-06-27 · 1 site observation
RECRUITING
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart FailureNCT06424288 · 2024-06-17 · 1 site observation
RECRUITING
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or ObesityNCT07575932 · 2026-05-11 · 1 site observation
ACTIVE_NOT_RECRUITING
Taldefgrobep Alfa in Adults With Overweight and ObesityNCT07281495 · 2025-11-24 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal InsulinNCT07215312 · 2025-10-13 · 1 site observation
ACTIVE_NOT_RECRUITING
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 DiabetesNCT07076199 · 2025-08-11 · 1 site observation
ACTIVE_NOT_RECRUITING
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)NCT07104383 · 2025-06-23 · 1 site observation
ACTIVE_NOT_RECRUITING
VK2735 for Weight Management Phase 3NCT07104500 · 2025-06-23 · 1 site observation
ACTIVE_NOT_RECRUITING
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or OverweightNCT06962280 · 2025-05-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Nipocalimab in Moderate to Severe Sjogren's DiseaseNCT06741969 · 2024-12-04 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)NCT06584916 · 2024-09-13 · 1 site observation
COMPLETED
A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related ComorbidityNCT06525935 · 2024-08-16 · 1 site observation
COMPLETED
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 DiabetesNCT06326047 · 2024-03-18 · 1 site observation
COMPLETED
Empowering Hispanic Patients' Lung Cancer Screening Uptake (Empower Latinx)NCT06225414 · 2024-02-12 · 1 site observation
COMPLETED
Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin DegludecNCT06238778 · 2023-12-28 · 1 site observation
COMPLETED
Empowering Patients' Lung Cancer Screening UptakeNCT06000683 · 2023-10-13 · 1 site observation
COMPLETED
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With MetforminNCT06045221 · 2023-09-22 · 1 site observation
COMPLETED
VK2735 for Weight Management Phase 2NCT06068946 · 2023-08-31 · 1 site observation
COMPLETED
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise AloneNCT05971940 · 2023-08-09 · 1 site observation
COMPLETED
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 DiabetesNCT05872620 · 2023-06-05 · 1 site observation
COMPLETED
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesNCT05869903 · 2023-06-05 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related ComorbiditiesNCT05822830 · 2023-04-21 · 1 site observation
COMPLETED
To Evaluate the Post-Prandial Metabolic Effects of Oligomalt in Adults With T2D and in HAONCT05963594 · 2023-01-23 · 1 site observation
COMPLETED
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes MellitusNCT05669599 · 2023-01-18 · 2 site observations
COMPLETED
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)NCT05662332 · 2023-01-14 · 1 site observation
COMPLETED
An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.NCT05562934 · 2022-11-08 · 1 site observation
COMPLETED
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With ObesityNCT05579977 · 2022-10-27 · 1 site observation
TERMINATED
A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid ArthritisNCT05516758 · 2022-08-31 · 1 site observation
TERMINATED
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)NCT05514535 · 2022-08-29 · 1 site observation
COMPLETED
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection TherapyNCT05463744 · 2022-08-12 · 1 site observation
COMPLETED
A Study to Investigate Safety, Tolerability, and PK of Oral Doses of TCK-276 in Patients With Rheumatoid ArthritisNCT05437419 · 2022-08-10 · 1 site observation
COMPLETED
A Research Study to Compare Two Semaglutide Medicines in People With Type 2 DiabetesNCT05478252 · 2022-08-03 · 1 site observation
COMPLETED
Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With ObesityNCT05406115 · 2022-07-26 · 1 site observation
COMPLETED
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)NCT05119855 · 2022-03-28 · 1 site observation
COMPLETED
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal InsulinNCT05275400 · 2022-03-08 · 1 site observation
COMPLETED
Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes MellitusNCT05114590 · 2022-01-27 · 1 site observation
COMPLETED
How to interpret this record
CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.